Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 3/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.55 |
| ▸ | PGR | P06401 | 2/20 | 0.49 |
| ▸ | CMA1 | P23946 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.42 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.42 |
| ▸ | PAK4 | O96013 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | RET | P07949 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29895649 | 1.00 | PDE3B (0.55) | PDE3BPDE3APGRCMA1CHEK1 | |
| SCHEMBL29477415 | 0.86 | CMA1 (0.61) | PDE3BPDE3APGRCMA1CHEK1 | |
| SCHEMBL289800 | 0.86 | CMA1 (0.61) | PDE3BPDE3APGRCMA1CHEK1 | |
| SCHEMBL5727262 | 0.76 | POLB (0.49) | PDE3BPDE3APGRALDH1A1KIF11 | |
| SCHEMBL20106905 | 0.75 | PDE3B (0.55) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL1848968 | 0.75 | PDE3B (0.55) | PDE3BPDE3APGRCMA1ABL1 | |
| SCHEMBL6190639 | 0.75 | POLB (0.56) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL7709830 | 0.75 | PDE3B (0.55) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL435577 | 0.75 | PDE3B (0.59) | PDE3BPDE3APGRCMA1ALDH1A1 | |
| SCHEMBL6190902 | 0.75 | CMA1 (0.75) | PDE3BPDE3APGRCMA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113087683-B | Nitrogen-substituted benzothiazolinone XOR/URAT1 dual inhibitor and preparation method and application thereof | 华南理工大学 | 2022-04-22 | — | — | CN | claimed |
| CN-113087683-A | Nitrogen-substituted benzothiazolinone XOR/URAT1 dual inhibitor and preparation method and application thereof | 华南理工大学 | 2021-07-09 | — | — | CN | claimed |
| US-10655015-B2 | Tire crumb-based bitumen polymer for producing a lower viscosity asphalt with improved tolerance to high temperatures | Argopro Group LLC (US) | 2020-05-19 | — | — | US | claimed |
| US-20200095424-A1 | TIRE CRUMB-BASED BITUMEN POLYMER FOR PRODUCING A LOWER VISCOSITY ASPHALT WITH IMPROVED TOLERANCE TO HIGH TEMPERATURES | Argopro Group LLC | 2020-03-26 | — | — | US | claimed |
| EP-3976604-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2026-01-21 | — | — | EP | disclosed |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2025-10-07 | — | — | US | disclosed |
| WO-2025021062-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| US-20240294482-A1 | METHOD FOR CATALYTICALLY ACTIVATING CARBON DIOXIDE AS CARBONYLATION REAGENT WITH INORGANIC SULFUR | INNER MONGOLIA UNIVERSITY OF TECHNOLOGY (CN) | 2024-09-05 | — | — | US | disclosed |
| EP-4298097-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230391764-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-12-07 | — | — | US | disclosed |
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-10-19 | — | — | US | disclosed |
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | VIRGINIA TECH INTELLECTUAL PROPERTIES, INC. | 2023-10-19 | — | — | US | disclosed |
| US-6380235-B1 | USEFUL AS PROGESTERONE RECEPTOR AGONISTS AND ANTAGONISTS, USED FOR CONTRACEPTION, IN THERAPY OF FIBROIDS, ENDOMETRIOSIS, BREAST, UTERINE, OVARIAN AND PROSTATE CANCER, AND POST MENOPAUSAL HORMONE REPLACEMENT THERAPY | AMERICAN HOME PRODUCTS CORPORATION | 2002-04-30 | — | — | US | disclosed |
| US-20020045625-A1 | OXAZOLIDINONE CHEMOTHERAPEUTIC AGENTS | ABBOTT LABORATORIES | 2002-04-18 | — | — | US | disclosed |
| WO-2002018353-A2 | OXAZOLIDINONE CHEMOTHERAPEUTIC AGENTS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
| WO-2002014294-A2 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND THEIR USE FOR POTENTIATING GLUTAMATE RECEPTOR FUNCTION | ELI LILLY AND COMPANY (US) | 2002-02-21 | — | — | WO | disclosed |
| EP-1173213-A1 | COMPOSITIONS CONTAINING BENZIMIDAZOLONES AND PROGESTOGENS | American Home Products Corporation (US) | 2002-01-23 | — | — | EP | disclosed |
| WO-2002004444-A2 | HETEROCYCLE CARBOXAMIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2000066168-A1 | COMPOSITIONS CONTAINING BENZIMIDAZOLONES AND PROGESTOGENS | AMERICAN HOME PRODUCTS CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
| EP-1043319-A1 | NOVEL ALKYLAMINO DERIVATIVES | MITSUBISHI CHEMICAL CORPORATION (JP) | 2000-10-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294482-A1 | METHOD FOR CATALYTICALLY ACTIVATING CARBON DIOXIDE AS CARBONYLATION REAGENT WITH INORGANIC SULFUR | TST, CBR3, SMOX | PDE3B 4085/4885PDE3A 4059/4885PGR 4636/4885 |
| US-20230331683-A1 | INHIBITORS OF SPINSTER HOMOLOG 2 (SPNS2) FOR USE IN THERAPY | SPNS2, SPCS2, SMN1; SMN2 | PDE3B 3133/4885PDE3A 2819/4885PGR 3775/4885 |
| US-12435128-B2 | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 | INMT, CARM1, KDM1B | PDE3B 3346/4885PDE3A 2618/4885PGR 3381/4885 |
| US-20230391764-A1 | BENZOTHIAZOLYL BICYCLO[1.1.1]PENTANE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, SLC10A1, BCL2A1 | PDE3B 3933/4885PDE3A 3901/4885PGR 1418/4885 |
| US-20020045625-A1 | OXAZOLIDINONE CHEMOTHERAPEUTIC AGENTS | OXA1L, TK1, PDCD1 | PDE3B 2802/4885PDE3A 2321/4885PGR 2753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.